Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G M Besser

Showing results (401-410 of 407) with videos related to

Pageof 41
Sort By:
You have reached the last page of results.This site can display upto 407 results.
British Medical Journal|December 14, 1974
Long-term infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormonesG M Besser, C H Mortimer, A S McNeilly, et al.
Clinical Endocrinology|February 21, 2006
Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumoursK J Bradley, B M Cavaco, M R Bowl, et al.
American Journal of Human Genetics|April 16, 1998
Characterization of mutations in patients with multiple endocrine neoplasia type 1J H Bassett, S A Forbes, A A Pannett, et al.
QJM : Monthly Journal of the Association of Physicians|September 1, 1996
Clinical studies of multiple endocrine neoplasia type 1 (MEN1)D Trump, B Farren, C Wooding, et al.
Lancet (London, England)|December 6, 2001
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonistA J van der Lely, R K Hutson, P J Trainer, et al.
The New England Journal of Medicine|April 20, 2000
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomantP J Trainer, W M Drake, L Katznelson, et al.
Nature Genetics|November 16, 2002
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndromeJ D Carpten, C M Robbins, A Villablanca, et al.
Pageof 41

Showing results (401-410 of 407) with videos related to

Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 407 results.
British Medical Journal|December 14, 1974
Long-term infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormonesG M Besser, C H Mortimer, A S McNeilly, et al.
Clinical Endocrinology|February 21, 2006
Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumoursK J Bradley, B M Cavaco, M R Bowl, et al.
American Journal of Human Genetics|April 16, 1998
Characterization of mutations in patients with multiple endocrine neoplasia type 1J H Bassett, S A Forbes, A A Pannett, et al.
QJM : Monthly Journal of the Association of Physicians|September 1, 1996
Clinical studies of multiple endocrine neoplasia type 1 (MEN1)D Trump, B Farren, C Wooding, et al.
Lancet (London, England)|December 6, 2001
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonistA J van der Lely, R K Hutson, P J Trainer, et al.
The New England Journal of Medicine|April 20, 2000
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomantP J Trainer, W M Drake, L Katznelson, et al.
Nature Genetics|November 16, 2002
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndromeJ D Carpten, C M Robbins, A Villablanca, et al.
Pageof 41